NCT04588246: Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery

NCT04588246
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 3
Drug Category: Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have developed their first or second distant brain relapse(s) at least 8 weeks after upfront stereotactic radiosurgery (SRS); Metastases must measure less than or equal to 3.0 cm in maximal extent
Exclusions: Patients with prior whole brain radiation therapy or prophylactic cranial irradiation; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT04588246

Comments are closed.

Up ↑